Evidence map›Paper›PMID 21778329›Full record

ReviewCancer prevention research (Philadelphia, Pa.)2011

Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention.

Susan M Fischer, Ernest T Hawk, Ronald A Lubet

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer prevention research (Philadelphia, Pa.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 3 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 3 syntheses or guidelines pooled it, 115 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.The Canadian veterinary journal = La revue veterinaire canadienne · 2013
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Potential of Anti-inflammatory Molecules in the Chemoprevention of Breast Cancer.Recent advances in inflammation & allergy drug discovery · 2022
    Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Prostaglandin EGastroenterology · 2020
    Article
  17. Article
  18. Review
  19. Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Susan M FischerDepartment of Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Science Park, PO Box 389, Smithville, TX 78957, USA. smfischer@mdanderson.org
Ernest T Hawk
Ronald A Lubet
National Cancer Institute · USThe University of Texas MD Anderson Cancer Center · US

Funding

COX-2 in Skin CarcinogenesisR01CA100140 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FISCHER, SUSAN M · 2003 to 2007
$1.7M
NCI NIH HHS N01 CN053300NCI NIH HHS R01 CA100140
6 · The paper itself

Abstract

Coxibs, including celecoxib, and other nonsteroidal anti-inflammatory drugs (NSAID), including aspirin, are among the most promising cancer chemopreventive agents in development today. This article examines the data on the efficacy of these agents in animal model studies of cancer prevention carried out by the authors. The studies evaluated here are restricted to our rodent models of colon/intestinal, bladder, and nonmelanoma skin cancer, in which celecoxib and other NSAIDs were administered as either cancer preventive or therapeutic agents. These studies may shed light on several questions. Is celecoxib unique compared with other NSAIDs, and if so, what implications would this have for human use? Are standard NSAIDs (which inhibit both COX-1 and COX-2) as effective as celecoxib in animal studies? Is the efficacy of celecoxib in particular or NSAIDs in general due to their off-target effects or to their effects on COX-1 and COX-2? What is the likely efficacy of low-dose aspirin? Some questions raised by human trials and epidemiology are discussed and related to our observations in animal model studies. We also discuss the problem of cardiovascular (CV) events associated with coxibs and certain other NSAIDs and whether results in animal models are predictive of efficacy in humans. On the basis of epidemiologic studies and its CV profile, aspirin seems to be the most promising NSAID for preventing human colorectal, bladder, and skin cancer, although the animal data for aspirin are less clear. A comprehensive understanding of the results of coxibs and other NSAIDs in animal studies may help inform and shape human trials of these commonly employed, relatively inexpensive, and highly effective compounds.

Indexed as

Disease Models, AnimalAnimalsAnti-Inflammatory Agents, Non-SteroidalCyclooxygenase 2 InhibitorsHumansNeoplasmsAnti-Inflammatory Agents, Non-SteroidalCyclooxygenase 2 Inhibitors

Identifiers

PMID21778329
PMCPMC3208782
OpenAlexW2168125951

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.